ASCO20: MET Inhibitor for Lung Cancer With MET Exon 14 Skipping Mutation
Posted: Saturday, June 13, 2020
According to Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues, patients with advanced non–small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation appears to derive durable clinical benefits from the MET inhibitor tepotinib. The results from cohort A of the VISION trial, which were presented during the ASCO20 Virtual Scientific Program (Abstract 9556) and published in The New England Journal of Medicine, suggests this targeted therapy is safe and effective in patients with asymptomatic brain metastases.
“The success of this trial, alongside other studies on the same class of drugs, establishes METex14 as an actionable target for NSCLC,” Dr. Le commented in an MD Anderson press release. “We’re pleased to show that another group of [patients with] lung cancer may benefit from precision medicine.”
A total of 152 patients with advanced NSCLC and confirmed METex14 skipping underwent tepotinib therapy. The enrolled population included 11 patients with stable brain metastases. Each patient received an oral dose of 500 mg of tepotinib once daily. The responses of patients who had provided at least 9 months of follow-up data were assessed by the investigators and an independent review committee. The patients were divided into three analysis sets: liquid biopsy, tissue biopsy, and combined biopsy.
In the combined-biopsy group, the median progression-free survival times by independent review and investigator assessment were 8.6 and 9.5 months, respectively. The objective response rates were 43% and 56%, respectively. Similar overall response rates were observed in both the liquid- and tissue-biopsy groups. Independent review revealed a 55% objective response rate, and a median progression-free survival of 10.9 months in patients with brain metastases. A deep molecular response was observed in the majority of patients (67%) with matched liquid-biopsy samples. Treatment-emergent adverse events grade 3 or higher were reported in 25% of the patient population.
Disclosure: For full disclosures of the study authors, visit coi.asco.org.
